Jaguar Health, Inc. JAGX
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Jaguar Health, Inc. (JAGX) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to June 30, 2026 it had revenue of $28M and net income of -$52M, a net margin of -188.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -108%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.
About Jaguar Health
Jaguar Health is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $258381 in 2015 to $12M in 2025, growth of about 46.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 265932% over three years (dilution for shareholders). It spends 217% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28M | $12M | $12M | $10M | $12M | $4M | $9M | $6M | $4M | $4M | $141523 |
| Net income | -$52M | -$54M | -$38M | -$41900 | -$48400 | -$52600 | -$34M | -$39M | -$32M | -$22M | -$15M |
| Free cash flow | — | — | -$29M | — | -$33M | -$35M | -$15M | — | -$23M | — | -$15M |
| EPS (diluted) | $-35.94 | $-22.97 | $-130.69 | $-2678.17 | $-54122.01 | $-131969.15 | $-336579.96 | $-1010861.82 | $-17195870.23 | $-59608368.02 | $-159034157.84 |
| Net margin | -188.5% | -465.4% | -329.3% | -0.4% | -0.4% | -1.2% | -360.2% | -667.3% | -727.9% | -503.7% | -10410.9% |
| ROIC | — | -184.2% | -71.7% | -81.7% | -102.8% | -98.8% | -79.8% | -125.4% | -146.5% | -69.2% | -836.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Jaguar Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Jaguar Health pay a dividend?
Not currently.
Is Jaguar Health a good stock to buy?
We do not give buy or sell advice. Jaguar Health scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.